The University of Michigan Hepatology Program is one of the largest and most well-established programs in the country. Headed by Anna Lok, MD, FRCP, the Hepatology Program includes twelve faculty members with expertise in a wide variety of liver diseases. Our faculty practice in clinics based at the Taubman Center and the Veterans Affairs Healthcare System in Ann Arbor, and at University of Michigan satellite clinics in Canton and Livonia.
The mission of our Hepatology Clinics is to provide timely, innovative, and compassionate care to patients affected by liver diseases. As part of this mission, we provide multidisciplinary care at our Liver Transplant Clinics and Liver Tumor Clinics so patients can be evaluated by physicians from all appropriate disciplines during a single visit. In addition, we are actively engaged in clinical research into novel therapies, improved diagnostic modalities, and better biomarkers and predictors of outcome. All patients seen in any of our Hepatology Clinics who are potential candidates for new therapies and other research protocols are referred for participation in clinical trials.
Our faculty play key roles in multiple NIH-sponsored clinical research networks including
- Acute liver failure
- Biomarkers for early diagnosis of hepatocellular carcinoma.
- Drug-induced liver injury
- Hepatitis B
- Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C)
We are also involved in many clinical trials supported by pharmaceutical companies that evaluate new therapies for various liver diseases including hepatitis B and C, fatty liver, and hepatocellular carcinoma.
In addition to the General Hepatology Clinics, the U-M Hepatology Program has established the following subspecialty clinics:
